Search clinical trials for: LUM

Total 1084 results

Takeda

Completed

A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets

Healthy Adult Participants

Japan
H. Lundbeck A/S

Completed

Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder

Chile, Argentina, Colombia, Costa Rica, Estonia, Finland, France, Hungary, Peru, Russian Federation, South Africa
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women

Healthy

China
Yale University
National Cancer Institute (NCI)

Active, not recruiting

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (SMARTTT)

Tobacco Use Cessation

United States
South Plains Oncology Consortium
The Evan Foundation

Terminated

Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma (SPOC2013-001)

Neuroblastoma | Recurrent Neuroblastoma

United States
Duke University

Completed

Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)

Smoking

United States
National Institute of Mental Health (NIMH)

Completed

CATIE- Schizophrenia Trial

Schizophrenia

United States
Duke University
Durham VA Medical Center

Completed

Contingency Management for Smoking Cessation in Homeless Smokers

Smoking | Homeless Persons

United States
H. Lundbeck A/S

Terminated

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (Anew)

Treatment-resistant Schizophrenia

United States, Japan, Russian Federation, Bulgaria, United Kingdom
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
Laboratoires Thea

Completed

Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery

Cataract

France
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Sickle Cell Disease | Thalassemia | Thalassemia, Beta

United States
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Takeda
H. Lundbeck A/S

Completed

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Takeda
H. Lundbeck A/S

Completed

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Major Depressive Disorder

France, Ukraine, Germany, Malaysia, South Africa, Korea, Republic of, Russian Federation, Czech Republic, Lithuania, United Kingdom, Latvia, Australia, Netherlands, Poland, Taiwan
Takeda
H. Lundbeck A/S

Completed

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Generalized Anxiety Disorder

United States
Takeda

Completed

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Takeda

Completed

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Depressive Disorder, Major

Taiwan, Germany, Hong Kong, Poland, Malaysia, Romania, Serbia, Ukraine, Japan, Finland, Latvia, Croatia, India, Korea, Republic of, Philippines, Russian Federation
H. Lundbeck A/S

Completed

Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls

Depression

United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
PRA Health Sciences

Completed

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Schizophrenia | Bipolar I Disorder

United States
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes

Major Depressive Disorder
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Duke University

Completed

Mobile Contingency Management for Marijuana and Tobacco Cessation

Marijuana Abuse | Cigarette Smoking

United States
Duke University

Completed

Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD (QUIT4EVER)

Smoking | PTSD

United States
University Hospital, Basel, Switzerland
Swiss Cancer League

Recruiting

Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide (PROMENADE)

Meningioma

Switzerland
ITM Solucin GmbH
ABX CRO; PSI CRO

Active, not recruiting

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)

Neuroendocrine Tumors

Germany, France, United States, United Kingdom, Australia, Italy, Belgium, Switzerland, Czechia, Spain, Austria, Netherlands, Poland, South Africa
H. Lundbeck A/S

Terminated

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Depressive Disorder, Major

United States, Korea, Republic of, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Latvia, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Mexico, South Africa, United Kingdom
H. Lundbeck A/S

Completed

Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (FOCUS)

Major Depressive Disorder
Takeda
H. Lundbeck A/S

Completed

Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

Generalized Anxiety Disorder

Ukraine, Germany, Romania, Russian Federation, Lithuania, Latvia, Estonia, Poland
Takeda

Completed

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Depressive Disorder, Major

United States
Takeda
H. Lundbeck A/S

Completed

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Major Depressive Disorder

United States, France, United Kingdom, Germany, Malaysia, Serbia, South Africa, Ukraine, Taiwan, Korea, Republic of, Russian Federation, Lithuania, Latvia, Croatia, Australia, Netherlands, Poland
Takeda

Completed

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

Healthy

United States
Takeda
H. Lundbeck A/S

Completed

Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Mexico, Canada
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
H. Lundbeck A/S

Completed

Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

Drug Reactions

United Kingdom
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Duke University

Completed

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

Alcohol Drinking | Smoking Cessation

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Takeda

Completed

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Major Depressive Disorder

Japan
Duke University

Completed

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

Schizophrenia | Cigarette Smoking

United States
University of Toronto
Unity Health Toronto; Maple Leaf Research

Completed

Effects of Intensive cART During Acute/Early HIV Infection

Acute HIV Infection

Canada
Abbott

Completed

Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives (HOS)

Hypertension | Obesity
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

Major Depressive Disorder

Finland, Germany, Serbia, Slovakia, Estonia
Takeda

Completed

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Treatment Outcome

United States, Canada
University of Udine

Recruiting

The Supplementation Therapy in Autism and Response to Treatment Study (START)

Depressive Symptoms | Autism Spectrum Disorder | Anxiety State | Autism | Asperger Syndrome | Autism Spectrum Disorder High-Functioning

Italy
H. Lundbeck A/S

Completed

A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication (REVIVE)

Major Depressive Disorder
Joseph Valentino, MD

Recruiting

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (TTOP)

Smoking Cessation | Cancer, Treatment-Related

United States
Altria Client Services LLC
Celerion

Recruiting

Pharmacokinetic and Subjective Effects of Heated Tobacco Products

Tobacco Use

United States
H. Lundbeck A/S

Completed

Investigating the Effect of Vortioxetine in Adult ADHD Patients

Attention Deficit Hyperactivity Disorder

United States
H. Lundbeck A/S

Completed

Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder

Major Depressive Disorder

Finland, Germany, Serbia, Slovakia

Search clinical trials for: LUM

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations